MD-3-A45

Overview

MD-3-A45 is an inhibitor of fibroblast growth factor 23 ( FGF-23 ). MD-3-A45 blocks the activation of the FGFRs/α-klotho signaling pathway by FGF-23 and inhibits FGF-23-induced ERK activation. MD-3-A45 can be used in the research of chronic kidney disease, hereditary hypophosphatemic rickets and acquired hypophosphatemic rickets.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Mineral Metabolism | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > ERK | Products > Signaling Pathways > FGFR

Product Information

• Catalog No.: HY-186173
• CAS No.: 2314337-87-4
• Molecular Formula: C16H15NO
• Molecular Weight: 237.30
• Purity: 98.23%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 1.25 mg/mL (5.27 mM); Clear solution
• Availability: In-stock

Source

Original product source